Life Bio, Forge to develop gene therapies for aging-linked diseases
Life Biosciences has announced a cGMP manufacturing collaboration with Forge Biologics for advancing the development of new gene therapies to treat aging-related diseases.
Life Biosciences has announced a cGMP manufacturing collaboration with Forge Biologics for advancing the development of new gene therapies to treat aging-related diseases.
Biopharmaceutical company Neogap Therapeutics has partnered with Swiss company Cellerys for a Phase II study of the latter’s RED4MS therapy for multiple sclerosis.
Biopharmaceutical company Stablix and Vertex Pharmaceuticals have joined forces to discover and develop targeted protein stabilisation (TPS) therapies.
Boehringer Ingelheim has opened its new advanced Biologicals Development Center (BDC) in Biberach an der Riß, Germany.
ImmunoPrecise Antibodies (IPA) subsidiary, Talem Therapeutics has entered into a research collaboration and licence option agreement with Astellas Pharma’s wholly-owned subsidiary, Xyphos Biosciences.
Macomics and Ono Pharmaceutical have entered into a global collaboration deal for the discovery and development of macrophage-targeting antibody therapy for cancer.
Dewpoint Therapeutics has formed a research and development partnership with Novo Nordisk for identifying drug candidates to treat insulin resistance and diabetic complications.
Tempus has unveiled a multi-year strategic partnership with Pfizer for advancing the development of cancer drugs.
Biotechnology company Alchemab Therapeutics and Medicines Discovery Catapult (MDC) have received $2.06m (£1.7m) grant from Innovate UK to accelerate the development of disease modifying therapy to treat Huntington’s disease.
Biotechnology company Gilgamesh Pharmaceuticals has raised $39m in Series B financing round, led by Prime Movers Lab, for advancing treatments for mental health.